Thyroid cancer is a malignant neoplasm arising from thyroid tissue, with major histologic subtypes including papillary, follicular, medullary, and anaplastic carcinoma. Most cases are differentiated cancers with generally favorable outcomes when detected early.
A real-world analysis found BRAF V600E-mutated papillary thyroid cancer had a proinflammatory molecular profile, but no significant overall survival difference versus BRAF wild-type disease. Treatment choice among BRAF/MEK inhibitors, tyrosine kinase inhibitors, and immunotherapy was not associated with significant survival differences.
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
Bariatric surgery procedures have fallen 46.4% since 2022 as prescriptions for semaglutide and tirzepatide rose to 24.17% of eligible adults by Q3 2025, though 75.8% of eligible patients still receive no treatment.
Recent studies examine safety profiles of GLP-1 receptor agonists, finding increased risk for nonscarring hair loss but improved survival in patients with brain metastases and type 2 diabetes.
Oncology specialists are warning cancer patients against biotin supplementation, citing its capacity to distort critical laboratory test results including hormone panels used to monitor treatment and detect recurrence.
Phase 3 LIBRETTO-432 trial met its primary endpoint, showing selpercatinib delivered statistically significant and clinically meaningful improvement in event-free survival versus placebo as adjuvant therapy in early-stage RET fusion-positive NSCLC.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07600580 |
The Association Between Bilateral Intermediate Cervical Plexus Block During Total Thyroidectomy and Surgical Stress Response |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT07543887 |
Selpercatinib and Body Composition |
COMPLETED | |
| NCT07532356 |
Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk Stratification and Post-Treatment Surveillance in Fresh Thyroid Cancer Patients |
NOT_YET_RECRUITING | |
| NCT07524777 |
Ganoderma Spores Modulate the Gut-Brain Axis |
RECRUITING | NA |
| NCT07496684 |
Application and Evaluation of Vision-LSTM Modeling in Diagnostic Ultrasound Imaging of TI-RADS Category 4b Thyroid Nodules |
COMPLETED | |
| NCT07488858 |
Thyroidectomy: Microscopic Versus Conventional |
COMPLETED | NA |
| NCT07459283 |
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07438847 |
177Lu-CTR-FAPI for the Treatment of Thyroid Cancer |
RECRUITING | PHASE1 |
| NCT07436455 |
F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer |
RECRUITING | NA |
| NCT07433283 |
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor |
RECRUITING | PHASE1/PHASE2 |
